Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2025
The incidence of and mortality from cervical cancer are higher among rural-residing women versus their urban counterparts within the United States, according to a research letter published online March 3 in JAMA Network Open.
Read Full NewsPsychotropics are associated with increased BMI, and users with a high BMI genetic risk score and an unhealthy lifestyle have triple the risk for CVD, new research shows.
Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.
In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.
A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.
In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.
A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.
In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.
1.
Financial hardship common in patients with cancer
2.
A small rise in cancer was observed following the 1986 Chernobyl accident.
3.
Launch of the hereditary cancer clinic for precision oncology at Kokilaben Hospital.
4.
A new drug delivery system may help patients with a rare eye cancer
5.
Research team uncovers the underpinnings of head and neck cancers
1.
AI in Genomics: Decoding the Human Genome for Cancer Treatment
2.
Transforming Cancer Care: Metrics, Informatics, Equity, and Real-World Evidence
3.
Thyroid Cancer and Insulin Resistance: Unraveling the Complex Interplay for Better Patient Outcomes
4.
Elevating Hematology Oncology: Modern Approaches for Smarter Diagnosis and Treatment
5.
Revolutionizing Cancer Treatment with Trilaciclib: How a New Drug is Transforming Outcomes
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge